TELA Bio (NASDAQ:TELA) Issues Earnings Results

TELA Bio (NASDAQ:TELA) announced its quarterly earnings data on Thursday. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02), Zacks reports. TELA Bio had a negative net margin of 54.12% and a negative return on equity of 329.48%.

TELA Bio Price Performance

NASDAQ TELA traded down $0.03 during midday trading on Thursday, hitting $1.11. The company had a trading volume of 188,725 shares, compared to its average volume of 154,947. The firm has a 50-day moving average price of $1.46 and a 200-day moving average price of $1.58. The company has a market capitalization of $43.98 million, a PE ratio of -0.99 and a beta of 0.89. The company has a current ratio of 3.19, a quick ratio of 2.59 and a debt-to-equity ratio of 4.14. TELA Bio has a twelve month low of $0.86 and a twelve month high of $3.20.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of TELA Bio in a research note on Wednesday, October 8th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, TELA Bio currently has an average rating of “Hold” and an average price target of $4.50.

About TELA Bio

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.